BiotechTube
Ability Pharma

Ability Pharma

Barcelona, Spain· Est.
abilitypharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37M

Overview

Ability Pharma is a Spanish, private biotech founded in 2009, advancing a novel oncology platform based on autophagy-mediated cytotoxicity. Its lead asset, ABTL0812, is a first-in-class oral compound that has completed a Phase 2a trial in endometrial and lung cancers and is currently in a Phase 2b trial for metastatic pancreatic cancer. The company is pre-revenue, has secured strategic investment from SciClone Pharmaceuticals, and is targeting significant unmet needs in oncology with a differentiated mechanism of action.

Oncology

Technology Platform

Small molecule platform focused on inducing cytotoxic autophagy selectively in cancer cells, primarily through dual PPARα/γ agonism leading to ER stress and Akt/mTOR inhibition.

Funding History

4
Total raised:$37M
Series B$15M
Series A$10M
Grant$2M
Series A$10M

Opportunities

Positive Phase 2b data in pancreatic cancer, a high-mortality orphan disease, would be a major value inflection point and attract partnership or acquisition interest.
The favorable safety profile and oral administration support its potential as a backbone combination therapy across multiple solid tumors, expanding its market potential.
Orphan Drug Designation provides a pathway to accelerated approval and market exclusivity.

Risk Factors

High dependency on the success of a single asset, ABTL0812, in a challenging late-stage trial.
As a pre-revenue private company, it faces ongoing financing risks and may require dilution or unfavorable partnership terms to fund Phase 3 development.
The novel autophagy mechanism, while differentiating, carries inherent biological validation risks.

Competitive Landscape

The field of autophagy-inducing cancer therapeutics is emerging but not yet crowded with late-stage clinical candidates, offering a first-mover potential. However, ABTL0812 competes indirectly with all standard chemotherapies, targeted therapies, and immunotherapies in its target indications. Its success will depend on demonstrating superior efficacy or tolerability, particularly in combination settings.

More companies in Small Molecule Drugs →More companies in Spain →